open access

Vol 8, No 1 (2003)
Original papers
Published online: 2003-01-01
Submitted: 2002-11-21
Get Citation

Exclusive radiotherapy for non-small cell lung cancer. A retrospective multicentric study

D. Gouders, P. Maingon, M. Paesmans, P. Rodrigus, B. Hahn, M.D. Arnaiz, T. Nguyen, C. Landmann, J.F. Bosset, S. Danhier, P. Van Houtte
DOI: 10.1016/S1507-1367(03)70991-2
·
Rep Pract Oncol Radiother 2003;8(1):7-14.

open access

Vol 8, No 1 (2003)
Original papers
Published online: 2003-01-01
Submitted: 2002-11-21

Abstract

Purpose

To evaluate the daily practice of management of early inoperable lung cancer (stage I).

Materials and methods

The analysis was based on a questionnaire which was sent to participated centers. Between 1982 and 1994, 123 patients with an early stage I inoperable lung cancer were treated with definitive irradiation in the different institutions. The survival distributions were estimated by the Kaplan-Meier method. The following covarties were analyzed: age, gender, Karnofsky status, symptoms, diagnostic work-up, T stage, tumour size, tumour location, histology, respiratory and cardiac contra-indication. The univariate analysis was performed using log-rank test. Cox regression models were used to find the independent prognostic factors.

Results

: The 2 and 5-year survival rates were 34% and 8% respectively. The 5-year local failure rate was 42% for T1 and 82% for T2. In a multivariate analysis, the most important prognostic factors for survival were the performance status and the stage. After adjustment for these two covariates, the total dose delivered had no impact for the range of doses used in this series.

Conclusions

Our poor data outlined the needs for better radiation technique and for a better staging system.

Abstract

Purpose

To evaluate the daily practice of management of early inoperable lung cancer (stage I).

Materials and methods

The analysis was based on a questionnaire which was sent to participated centers. Between 1982 and 1994, 123 patients with an early stage I inoperable lung cancer were treated with definitive irradiation in the different institutions. The survival distributions were estimated by the Kaplan-Meier method. The following covarties were analyzed: age, gender, Karnofsky status, symptoms, diagnostic work-up, T stage, tumour size, tumour location, histology, respiratory and cardiac contra-indication. The univariate analysis was performed using log-rank test. Cox regression models were used to find the independent prognostic factors.

Results

: The 2 and 5-year survival rates were 34% and 8% respectively. The 5-year local failure rate was 42% for T1 and 82% for T2. In a multivariate analysis, the most important prognostic factors for survival were the performance status and the stage. After adjustment for these two covariates, the total dose delivered had no impact for the range of doses used in this series.

Conclusions

Our poor data outlined the needs for better radiation technique and for a better staging system.

Get Citation
About this article
Title

Exclusive radiotherapy for non-small cell lung cancer. A retrospective multicentric study

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 8, No 1 (2003)

Pages

7-14

Published online

2003-01-01

DOI

10.1016/S1507-1367(03)70991-2

Bibliographic record

Rep Pract Oncol Radiother 2003;8(1):7-14.

Authors

D. Gouders
P. Maingon
M. Paesmans
P. Rodrigus
B. Hahn
M.D. Arnaiz
T. Nguyen
C. Landmann
J.F. Bosset
S. Danhier
P. Van Houtte

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl